Xu Zewei is not the first alleged Chinese spy to be caught in America’s legal net. But this case is the first involving purely cyber activity https://t.co/lvUay5SYDH ...

Core Insights - Aehr Test Systems experienced significant stock volatility in 2025, with a 22.2% decline in the first half, following a 56% drop in the first quarter and a subsequent 77.4% rise in the last quarter of the half-year [1][2]. Financial Performance - The company's financial year ends on May 30, and for the fiscal year 2024, the silicon carbide (SiC) wafer-level burn-in (WLBI) market accounted for 90% of its sales [2]. - In fiscal year 2025, SiC WLBI revenue dropped to less than 40% of total revenue, indicating a significant shift in the company's revenue sources [4]. Market Dynamics - ON Semiconductor, a key customer, has faced a sales slowdown, reflecting a broader downturn in the SiC market, particularly in the electric vehicle (EV) sector, influenced by high interest rates and a correction from previous EV spending booms [3]. - The weakening EV market negatively impacted Aehr's growth prospects in the SiC WLBI market during the first three months of fiscal 2025 [4]. Strategic Developments - A turnaround in Aehr's stock occurred after the third-quarter earnings report in April, where management announced plans to expand into new markets, projecting that 35% of revenue would come from the artificial intelligence (AI) processor burn-in market [5]. - The company has secured four customers contributing over 10% of revenue, with three of these being in new markets, including gallium nitride (GaN) semiconductor supply for the automotive sector [5]. Customer Base and Future Outlook - Aehr has identified a major hyperscaler as a first production AI customer in the packaged part burn-in (PPBI) market, with notable customers including Microsoft, Google, Nvidia, ON Semiconductor, and Infineon [7]. - Management believes that AI end markets could be 3 to 5 times larger than traditional SiC markets, which is driving optimism and strength in the current stock price [8].

your your claim calls um malicious prosecution. You weren't charged with a crime yet. You were held for 104 days.Yeah. Thank you. Thank you so much for for having me.Um as you said, um I was detained for 144 days uh illegally. Um I missed the birth of my first child. um all for uh literally protesting and speaking out uh for Palestine and against the genocide in Gaza.Um I was not in in in any way accused of any crime. Um and there must be accountability. That's why I'm bringing uh this lawsuit against the a ...

🔍 INSIGHT: Running a Bitcoin Lightning node can generate income, but it’s not passive.Earnings depend on liquidity, uptime, and network routing success. https://t.co/lUXQZCrjkQ ...

Joining me now, we have Megan Hayes, former special assistant to President Biden and former director of message planning for the Biden administration. So, Democrats have high hopes for the midterm elections, especially with what they see as ammunition from this big policy bill. Senator Chuck Schumer are saying that it boosted Democrats chances of taking back the Senate.So, what is the message they need to focus on. And how should they go about countering Republican push back. I think they've been doing a re ...

If you are an athlete in search of a chemical boost your options are limited. An exception is creatine, a staple of sports nutrition and one of the few supplements with a solid evidence base behind it https://t.co/Bd6kxGiFCh ...

President Trump now says the US is going to resume sending arms shipments to Ukraine after a temporary pause. Trump announced this week that the US would supply weapons to Ukraine via NATO. The Trump administration has also been attempting to negotiate a peace deal to end the war in Ukraine.That's come up short. Those negotiations hit a snag. Our European allies are finding other ways to try to hold Putin accountable.In fact, a few weeks ago, Ukraine and the Council of Europe launched a special tribunal for ...

Donald Trump’s populism, and the contortions it creates for his party, is often treated as a new phenomenon in American politics. In fact, it is the latest expression of a decades-old identity crisis https://t.co/nFupQJAf6PIllustration: David Simonds https://t.co/8jwEp46zZc ...

Core Insights - Rhythm Pharmaceuticals presented new data on acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025), highlighting the efficacy of setmelanotide and bivamelagon in reducing body mass index (BMI) in affected patients [1][2][3] Group 1: Clinical Data and Efficacy - The Phase 3 TRANSCEND trial demonstrated significant BMI reductions with setmelanotide, showing a -9.3% reduction in the 600mg cohort, -7.7% in the 400mg cohort, and -2.7% in the 200mg cohort, while the placebo cohort experienced a 2.2% increase [4][5] - A placebo-adjusted difference of -19.8% in BMI reduction was observed across 120 participants, with significant reductions noted in various age and sex subgroups [5][6] - Bivamelagon, a daily oral MC4R agonist, also showed statistically significant BMI reductions in a Phase 2 trial, indicating its potential as a transformative treatment option for patients with acquired hypothalamic obesity [2][3] Group 2: Patient Population and Market Potential - Acquired hypothalamic obesity is a rare condition affecting an estimated 5,000 to 10,000 individuals in the U.S., with similar prevalence in Japan and the E.U. [11][10] - The condition is characterized by rapid weight gain and hyperphagia due to damage to the hypothalamic region of the brain, often following brain tumors or their treatment [10][11] - The presentations at ENDO 2025 underscore the potential for MC4R-targeted therapies to become the standard of care for this patient community if approved [2][3]

From @WSJopinion: The President is grasping what some of his staffers don’t: Arming Ukraine is realism rooted in America’s security interests https://t.co/Z61vV4N2mw ...